Panama7/iStock Editorial via Getty Images
- Provention Bio (NASDAQ:PRVB) rose 3.1% in premarket trading after the HSR antitrust waiting period for the company's sale to Sanofi (NASDAQ:SNY) expired. Sanofi rose 1%.
- Sanofi (SNY) announced that the HSR waiting period for the Provention Bio (PRVB) deal had expired in a statement.
- Sanofi (SNY) agreed to acquire diabetes drugmaker Provention Bio (PRVB) for ~$2.9 billion, or $25 a share last month.